Sofinnova Ventures Inc Buys NuCana PLC, Gilead Sciences Inc, Incyte Corp, Sells Ascendis Pharma A/S, Allergan PLC, Alexion Pharmaceuticals Inc

• New Purchases: GILD, BMRN, INCY, RETA, XNCR, DCPH, ICPT, CLVS, NBIX, MGNX, FGEN, FPRX, GWPH, IMGN, OSMT, PCRX,
• Added Positions: NCNA, MOR, AZN, ACRS, FOLD, SRPT, KALA, EPZM, HRTX, FATE, SNDX, FOMX, SVRA, DERM, RIGL, CNAT, OTIC,
• Reduced Positions: ASND, APLS, PBYI, ANAB, SNY, TSRO, BHVN, AIMT, PRNB, KDMN, CHMA,
• Sold Out: AGN, ALXN, EXEL, ADMS, CPRX, RYTM, KURA, BPMC, CLSD, MLLCF, SBPH, ARQL, ESPR, ADRO, ADAP, HSGX, OMED, EARS,

For the details of Sofinnova Ventures Inc's stock buys and sells, go to https://www.gurufocus.com/guru/sofinnova+ventures+inc/current-portfolio/portfolio

1. Ascendis Pharma A/S (ASND) - 1,498,538 shares, 12.36% of the total portfolio. Shares reduced by 39.56%
2. Amarin Corp PLC (AMRN) - 5,208,305 shares, 9.33% of the total portfolio.
3. ObsEva SA (OBSV) - 4,749,623 shares, 7.92% of the total portfolio.
4. Principia Biopharma Inc (PRNB) - 2,038,208 shares, 7.35% of the total portfolio. Shares reduced by 1.02%
5. Natera Inc (NTRA) - 3,100,560 shares, 5.70% of the total portfolio.

Sofinnova Ventures Inc initiated holding in Gilead Sciences Inc. The purchase prices were between $60.54 and $79, with an estimated average price of $69.57. The stock is now traded at around $65.85. The impact to a portfolio due to this purchase was 1.76%. The holding were 213,331 shares as of .

Sofinnova Ventures Inc initiated holding in Biomarin Pharmaceutical Inc. The purchase prices were between $80.14 and $106.07, with an estimated average price of $94.8. The stock is now traded at around $88.49. The impact to a portfolio due to this purchase was 1.58%. The holding were 140,542 shares as of .

Sofinnova Ventures Inc initiated holding in Incyte Corp. The purchase prices were between $58.5 and $69.94, with an estimated average price of $64.77. The stock is now traded at around $84.28. The impact to a portfolio due to this purchase was 1.58%. The holding were 188,497 shares as of .

Sofinnova Ventures Inc initiated holding in Reata Pharmaceuticals Inc. The purchase prices were between $48.76 and $76.44, with an estimated average price of $60.66. The stock is now traded at around $89.57. The impact to a portfolio due to this purchase was 1.17%. The holding were 157,984 shares as of .

Sofinnova Ventures Inc initiated holding in Xencor Inc. The purchase prices were between $32.39 and $42.05, with an estimated average price of $36.73. The stock is now traded at around $31.78. The impact to a portfolio due to this purchase was 0.95%. The holding were 199,682 shares as of .

Sofinnova Ventures Inc initiated holding in Deciphera Pharmaceuticals Inc. The purchase prices were between $19.08 and $36.14, with an estimated average price of $24.36. The stock is now traded at around $27.14. The impact to a portfolio due to this purchase was 0.73%. The holding were 265,475 shares as of .

Sofinnova Ventures Inc added to a holding in NuCana PLC by 240.00%. The purchase prices were between $13 and $22.4, with an estimated average price of $17.65. The stock is now traded at around $11.69. The impact to a portfolio due to this purchase was 3.06%. The holding were 2,266,666 shares as of .

Sofinnova Ventures Inc added to a holding in MorphoSys AG by 168.45%. The purchase prices were between $78.05 and $109.4, with an estimated average price of $92.47. The stock is now traded at around $94.10. The impact to a portfolio due to this purchase was 0.68%. The holding were 80,536 shares as of .

Sofinnova Ventures Inc added to a holding in AstraZeneca PLC by 31.47%. The purchase prices were between $36.86 and $41.49, with an estimated average price of $39.03. The stock is now traded at around $40.80. The impact to a portfolio due to this purchase was 0.38%. The holding were 316,328 shares as of .

Sofinnova Ventures Inc added to a holding in Aclaris Therapeutics Inc by 24.17%. The purchase prices were between $6.3 and $15.4, with an estimated average price of $10.13. The stock is now traded at around $6.57. The impact to a portfolio due to this purchase was 0.36%. The holding were 1,911,573 shares as of .

Sofinnova Ventures Inc added to a holding in Amicus Therapeutics Inc by 51.27%. The purchase prices were between $8.38 and $13.44, with an estimated average price of $10.9. The stock is now traded at around $11.59. The impact to a portfolio due to this purchase was 0.29%. The holding were 674,636 shares as of .

Sofinnova Ventures Inc added to a holding in Sarepta Therapeutics Inc by 63.44%. The purchase prices were between $97.32 and $147.38, with an estimated average price of $124.11. The stock is now traded at around $138.72. The impact to a portfolio due to this purchase was 0.27%. The holding were 48,894 shares as of .

Sofinnova Ventures Inc sold out a holding in Allergan PLC. The sale prices were between $129.82 and $193.46, with an estimated average price of $162.67.

Sofinnova Ventures Inc sold out a holding in Alexion Pharmaceuticals Inc. The sale prices were between $93.94 and $136.71, with an estimated average price of $117.6.

Sofinnova Ventures Inc sold out a holding in Exelixis Inc. The sale prices were between $13.65 and $21.8, with an estimated average price of $17.87.

Sofinnova Ventures Inc sold out a holding in Adamas Pharmaceuticals Inc. The sale prices were between $7.75 and $19.98, with an estimated average price of $12.75.

Sofinnova Ventures Inc sold out a holding in Catalyst Pharmaceuticals Inc. The sale prices were between $1.92 and $3.58, with an estimated average price of $2.83.

Sofinnova Ventures Inc sold out a holding in Rhythm Pharmaceuticals Inc. The sale prices were between $24.11 and $31.34, with an estimated average price of $27.63.